Corcept Therapeutics Inc(CORT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 5:20 PM ET (Korea 9/11 06:20)
Full metrics table
| Index | - | P/E | 274.47 | EPS (ttm) | 0.42 | Insider Own | 11.39% | Shs Outstand | 107.9M | Perf Week | 4.07% |
| Market Cap | 12.42B | Forward P/E | 26.78 | EPS next Y | 108.21% | Insider Trans | -5.76% | Shs Float | 95.8M | Perf Month | 2.74% |
| Enterprise Value | 12.12B | PEG | 0.25 | EPS next Q | 0.81 | Inst Own | 75.8% | Short Float | 10.12% | Perf Quarter | 47.11% |
| Income | 0.05B | P/S | 14.95 | EPS this Y | 151.31% | Inst Trans | 2.42% | Short Ratio | 9.04 | Perf Half Y | 240.6% |
| Sales | 0.83B | P/B | 17.57 | EPS next 5Y | 105.49% | ROA | 6.41% | Short Interest | 9.70M | Perf YTD | 230.23% |
| Book/sh | 6.54 | P/C | 40.31 | EPS past 3/5Y | -2.15% -0.84% | ROE | 8.08% | 52W High | -9.07% ($126.38) | Perf Year | 60.46% |
| Cash/sh | 2.85 | P/FCF | 116.19 | Sales past 3/5Y | 23.74% 16.56% | ROIC | 7.6% | 52W Low | 300.98% ($28.66) | Perf 3Y | 248.88% |
| Dividend Est. | - | EV/EBITDA | 1374.59 | EPS Y/Y TTM | -59.24% | Gross Margin | 98.3% | Volatility(W/M) | 4.72% 3.74% | Perf 5Y | 444.64% |
| Dividend TTM | - | EV/Sales | 14.59 | Sales Y/Y TTM | 16.02% | Oper. Margin | 0.77% | ATR (14) | 4.65 | Perf 10Y | 1997.08% |
| Dividend Ex-Date | - | Quick Ratio | 2.74 | EPS Q/Q | 23.91% | Profit Margin | 6.52% | RSI (14) | 54.92 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.83 | Sales Q/Q | 31.74% | SMA20 | -1.19% ($116.3) | Beta | 0.4 | Target Price | $141 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/29 | SMA50 | 8.7% ($105.72) | Rel Volume | 0.57 | Prev Close | $115.7 |
| Employees | 730 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 1381.48% 15.83% | SMA200 | 70.49% ($67.41) | Avg Volume(3M) | 1.07M | Price | $114.92 |
| IPO | 2004/4/14 | Option/Short | Yes/Yes | Trades | 10965 | Volume | 613,634 | Change | -0.67% |
Company
CORT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a US commercial-stage biotech company that develops and sells therapeutics based on the mechanism of cortisol (the stress hormone) regulation. It generates revenue and profit by selling treatments for Cushing's syndrome, and is a healthcare stock whose performance is tied to the launch of newly approved therapies and pipeline expansion.
Over the past 1 year, on the higher side
9% below its 1-year high.
CORT makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +151.3% this year.
Tap to view numbers
The price looks about right
Trading at 274.5 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +248.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 75.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.06%
LFSC 0.05%
PJP 0.04%
PSCH 0.03%
SURI 0.03%It ranks #4 in the industry
Based on market cap of $12B.
CORT $12B PER 274.5
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is CORT?
CORT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CORT?
The market cap of CORT is approximately $12.4B, ranking 815 within its sector.
What is the P/E ratio of CORT?
CORT has a P/E ratio of approximately 274.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CORT?
CORT has recorded a 52-week high of $126.38 and a low of $28.66.
